Biohaven Pharmaceutical Holding Current Ratio 2016-2021 | BHVN

Current and historical current ratio for Biohaven Pharmaceutical Holding (BHVN) from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Biohaven Pharmaceutical Holding current ratio for the three months ending June 30, 2021 was 1.67.
Biohaven Pharmaceutical Holding Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.67B $0.40B 1.67
2021-03-31 $0.90B $0.40B 2.28
2020-12-31 $0.60B $0.28B 2.17
2020-09-30 $0.71B $0.22B 3.26
2020-06-30 $0.36B $0.17B 2.18
2020-03-31 $0.47B $0.12B 3.89
2019-12-31 $0.33B $0.07B 4.96
2019-09-30 $0.42B $0.05B 8.96
2019-06-30 $0.47B $0.05B 10.62
2019-03-31 $0.23B $0.02B 9.60
2018-12-31 $0.27B $0.02B 13.94
2018-09-30 $0.18B $0.02B 11.99
2018-06-30 $0.23B $0.01B 17.84
2018-03-31 $0.12B $0.02B 6.80
2017-12-31 $0.14B $0.01B 14.49
2017-09-30 $0.18B $0.02B 8.12
2017-06-30 $0.21B $0.02B 11.91
2017-03-31 $0.05B $0.02B 3.44
2016-12-31 $0.02B $0.01B 3.03
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B $0.00B 5.88
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.865B $0.064B
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71